Atlas Trials

Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor

Clinical trial NCT03279601 · UNKNOWN

Trial details

NCT number
NCT03279601
Sponsor
Peking University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Neuroendocrine Tumors
Start date
2017-09-01
Primary completion
2019-09-01
Enrollment
148

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.